Dr. Christina Chang, FDA Director of the Division of Urology, Obstetrics and Gynecology to Join Panel Discussing Patient Reported Outcomes through the Lens of IUD Insertion Pain (more…)
Access to Wexford Knowledge Community Platform Supports Creation of a Women’s Health Science Hub Presence within UM BioPark Ecosystem and Provides Critical Connections for Growth (more…)
Poulos, former Head of Business Development at AbbVie, brings significant operational experience to support the Company’s growth strategy in women’s health (more…)
Mansfield, MA., Nov. 25, 2024 – 3Daughters, Inc., a clinical development company fueling evolutionary healthcare for women, is proud to be honored as a 2024 Eddy Award winner at the…
NICHD to Support Evaluation of Copper Release Characteristics of 3D-001 in a Preclinical Model, as Company Prepares for Phase 1 Clinical Trial (more…)
Funds will support development of game-changing IUD (intrauterine device) for contraception through an IND filing in early 2025 (more…)
Mansfield, MA., May 23, 2024 – 3Daughters, Inc., a clinical development company fueling evolutionary healthcare for women, announced that Mary Beth Cicero, Co-Founder and CEO, will participate in an expert…
Mansfield, MA., April 19, 2024 – 3Daughters, Inc., a clinical development company fueling evolutionary healthcare for women, was voted the “Startup of Year” by top life science investors and venture…
Board will help advance the mission and support development of our game-changing IUD for contraception (3D-001)Mansfield, MA., March 12, 2024 – 3Daughters, a clinical development company fueling evolutionary healthcare for…
Funding will accelerate development of a Novel IUD for contraception for IND filing in 2024 MANSFIELD, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- 3Daughters, a clinical development company fueling evolutionary…
©2025. All rights reserved
Louis Scotti, over the course of his 35-year biopharma career, has built and led teams in diverse areas, including business and corporate development, marketing, investor/public relations and strategic planning. He has negotiated over twenty-five revenue-producing partnerships for biopharma companies. While Senior Vice President, Louis led the due diligence and sale of IriSys LLC to Societal CDMO in August 2021 and successfully obtained multiple research and clinical supply contracts with government research organizations, including the NIH, NCI and NCATS. Previously, he was Vice President Commercial Planning, Business Development and Marketing for Arena Pharmaceuticals. He started his career at Bristol-Myers as Manager, New Products Marketing. Louis was educated at the University of Pennsylvania where he obtained a B.Sc. in Bioengineering.
Mr. Jacobs is an operations executive with an extensive engineering background in devices for Women’s Health. He headed up Boston Engineering’s Medical Devices practice and previously served as Chief Operating Officer at Scion Medical (devices for breast biopsy) and Vice President of Operations at Interlace Medical (MyoSure, device for removal of fibroids/polyps), acquired by Hologic. He is also an Adjunct Professor, Operations Management, Bentley University. His education includes a BSME Northeastern University and a MBA, Bentley University.
Shelley Amster has over 45 years of experience in women’s healthcare and reproductive endocrinology, including clinical andrology and IVF embryology.
She recognized the value of a frameless, magnetic technology for targeted delivery of contraceptive drugs to the uterus. With her experience in and knowledge of embryo transfer procedures, she assisted with the development of 3Daughters’ patented Slider™ inserter/retriever system to address the pain of IUD insertion and removal.
She is a well-known and respected advisor to the greater Massachusetts life sciences community.
Sharon Choe is Head of Investor Relations for 3Daughters where she is responsible for strategy and investor outreach for all fundraising activities for the current Series A ($15M) raise. Sharon has over 30 years of investor relations experience and background as a healthcare and biotech analyst on Wall Street. . She is an industry veteran with extensive IR experience, having served as Head of IR at Ocugen, a rare diseases company, and SVP, Head of Investor Outreach and Corporate Access for LaVoieHealthScience. Prior to that, she was Senior Vice President at The Ruth Group and Managing Director at Life Sci Advisors. Earlier in her career, Sharon worked on the buy side as a healthcare & biotech analyst at UBS Asset Management, Credit Suisse Asset Management and BAM Capital LLC. She has a BS in Pharmacy from Northeastern University.
Georgina joined 3Daughters in November 2023 after graduating summa cum laude from the University of Massachusetts Boston with a BA in Communication Studies, having also won the David Nyhan Award in her subject. While studying part-time she had previously worked as a Concierge at CIC Cambridge, a flexible workspace campus in the city’s famed Kendall Square area that gave her experience in the high-energy, fast-paced environment of start-up companies.
Wendy Blanda is a scientist, manager, and team leader with over 20 years of drug-device combination product experience. Wendy has a track record of taking new and novel sustained release drug delivery implants from proof of concept to commercialization and is leading 3Daughters’ CMC and product development efforts. She has extensive experience in Women’s Healthcare products, most notably the Dapivirine Ring for HIV prevention. She brings an understanding of data-based decision making and practical solutions to meet timelines and milestones for our regulatory filings. Wendy is a co-inventor on over 20 patents and completed a PhD in Macromolecular Science and Engineering at University of Michigan. She has an MS in Engineering Management from California State University and a BSc in Polymer Chemistry from at California Polytechnic State University.
Michael Vergano has an extensive career of executive management positions and a 30-year track record of contributions to product development, operations efficiencies, and profit enhancement in medical device and consumer products industries. Michael is leading the 3Daughters project management activities. He has been involved in medical device start-ups and has experience in product system process design and validation, as has a background in regulatory and quality. Previously, he was Director of Operations and Product Development at Apple Medical, Inc. and its division INSIGHT Medical, and has served in several engineering management roles for Ciba Corning Diagnostics, MicroSurge, Inc. and Boston Scientific Corporation. Michael is a certified medical device auditor (CMDA). He has a BSc degree in Mechanical Engineering from Tufts University.
Dr. Bill Bracken, certified by the American Board of Toxicology, provides leadership and guidance in areas of nonclinical safety assessment for drug development, including toxicology, pathology, and safety pharmacology. Bill is leading the 3Daughters preclinical program and the safety studies needed for our IND and NDA. He has held senior roles at AbbVie as Director of Global Preclinical Safety and Chair of the Drug Safety Committee. Dr. Bracken has also conducted expansive research on mechanisms of carcinogenicity at Oak Ridge National Labs, Fred Hutchinson Cancer Research Center, and the Midwest Research Institute. He completed his NIH Toxicology Fellowship at the University of Kansas Medical Center, received a MS and PhD in Toxicology from Utah State University, and has a BSc in Biology from University of Missouri – Kansas City.
Dr. Mahony is a medical affairs veteran with almost four decades of experience in reproductive medicine and endocrinology. Dr. Mahony recently served as EMD Serono’s Vice President of Fertility and Endocrinology where she led the medical team for pharmaceutical products and IVF laboratory medical devices. She is also an Associate Professor & Division Director of Reproductive Sciences at the OB/GYN Department at the Eastern Virginia Medical School and has extensive publication and journal credits in this field.
Dr. Gary Shangold brings over 30 years of executive, medical, and scientific experience as a reproductive endocrinologist. He has served as CMO of Enteris BioPharma and Xanodyne Pharmaceuticals. Dr. Shangold also served as CEO of NovaDel Pharma. He has previously held senior roles in clinical research and regulatory affairs at RW Johnson Pharmaceutical R&D (Johnson & Johnson) and served as Medical Director for the OB/GYN/Infertility unit at Serono Labs (now EMD Serono). Dr. Shangold completed his Fellowship in Reproductive Endocrinology at the University of Southern California and his residency in Obstetrics & Gynecology at the University of Miami. He completed an MD at Columbia University and a BA in Social Behavior (cum laude) at University of Pennsylvania.
Dr. Gradil is a world renowned veterinary reproductive specialist and is dedicated to providing comprehensive breeding and reproductive care for horses. He is Director of University of Massachusetts, Equine Program and an Extension Associate Professor. Dr. Gradil also leads the Reproductive Medicine Service, at the Cummings School of Veterinary Medicine, Tufts University.
Dr. Gradil obtained his M.S./Ph.D. at the University of Minnesota and his DVM from the University of Lisbon, Portugal. His postdoctoral training was completed at the University of Minnesota, the University of Ottawa, and Cornell University. His Honors and other distinctions include: AID, Fulbright, NATO, Rockefeller Fellow. Phi Zeta, Kappa Chapter and Diplomate of the American College of Theriogenology.
David F. Archer, MD, is Professor of Obstetrics and Gynecology, and Director of the Clinical Research Center. He is a member of the CONRAD program that is involved in developing combination products for contraception and prevention of heterosexual transmission of HIV virus. He is a Fellow of the American Congress of Obstetrics and Gynecology, and member of the American Society for Reproductive Medicine, the North American Menopause Society, and the International Menopause Society. Dr. Archer has served on the Boards of the American Society for Reproductive Medicine, and the North American Menopause Society (NAMS). He is a Board member of the Anne and Egon Diczfalusy Foundation. Dr. Archer has been President of the Society of Reproductive Endocrinology and Infertility (SREI), and the North American Menopause Society. He is the recipient of a NAMS Award for Perimenopausal contraception, the Association of Reproductive Health Professionals Alan F. Guttmacher Award, and the Eastern Virginia Medical School Deans Award for Outstanding Research. He is on the Editorial Board of Menopause, Contraception, and Contraceptive Technology. His publications are related to hormones and menopause, contraception, and reproductive endocrinology. His current research is on the mechanisms involved in abnormal endometrial bleeding.
John F. Vacha has extensive experience serving in numerous CFO roles with and has a background in finance, board advisory roles, strategic planning, and fundraising. He began his career at Deloitte & Touche, LLP. Over the past 24 years, he has served as Vice President, CFO, and Treasurer at Intact Medical Corporation (acquired by Medtronic). He has in-depth knowledge and experience working in the women’s healthcare field. John is a licensed CPA in Massachusetts and holds an MBA and MSA in Business & Accounting from Northeastern University and a BA in Psychology from College of the Holy Cross.
Mary Beth Cicero has over 40 years of executive leadership roles in marketing and business development. She has significant professional experience in Women’s Healthcare, having spent the greater part of her career working in contraception, fertility, and most disease states that affect women. Mary Beth was formerly President of MarketSense Ltd., a healthcare consulting firm, where she worked with over 100 clients on marketing assessments, partnering activities, fundraising, market research, and every aspect of licensing. She served as Vice President of Business Development for Agile Therapeutics (Twirla®) for over seven years. Other previous positions include Vice President of Business Development at two biotechnology companies. Prior to that time, she led US marketing for Serono Labs (now EMD Serono) focusing on infertility treatments. Mary Beth’s educational background includes a BSc in Biology (cum laude) from Boston College and an MBA in Marketing from Babson College. In addition to her professional responsibilities, she teaches a course entitled “Marketing Principles and Applications for Pharma Entrepreneurs” for the Jie Du Center for Innovation at the University of the Pacific.